Fluorofenidone (Standard)

Fluorofenidone (Standard) is the analytical standard of Fluorofenidone (AKF-PD) (HY-121246) . This product is intended for research and analytical applications. Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) [1][2][3].

Product Specifications

CAS Number

[848353-85-5]

UNSPSC

12352100

Target

ERK; NF-κB; Reference Standards; TGF-beta/Smad

Related Pathways

MAPK/ERK Pathway; NF-κB; Others; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Inflammation/Immunology

Smiles

O=C1C=CC(C)=CN1C2=CC=CC(F)=C2

Molecular Formula

C12H10FNO

Molecular Weight

203.21

References & Citations

[1]Wu Y, et al. Fluorofenidone alleviates cigarette smoke exposure-induced chronic lung injury by targeting ferroptosis. Sci Rep. 2024 Dec 30;14 (1) :32149.|[2]Wang H, et al. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868 (12) :166556.|[3]Wang S, et al. Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression. Transl Lung Cancer Res. 2024 Nov 30;13 (11) :3175-3188.